Medically Reviewed By
Dr. Aditya Singh, MBBS, MD (Pharmacology)
Reg No: MCI-654321 • Verified Medical Reviewer
Jemperli
(dostarlimab)
Uses, side effects, dosage information & price range
About this medicine
Jemperli is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy. Jemperli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability?high (MSI?H) recurrent or advanced EC that has progressed on or following prior treatment with a platinum?containing regimen.
Common Brand Names for this Composition
The following popular commercial brand names contain dostarlimab as their active ingredient composition:
Jemperli
GlaxoSmithKline Trading Services Limited
Key Information
Salt / Composition
dostarlimab
Category
Antineoplastic Agents and Antibody Drug Conjugates
Manufacturer
GlaxoSmithKline Trading Services Limited
Medical Disclaimer
This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your doctor or pharmacist before taking any medication. Prices are indicative and may vary. Do not start, stop, or change the dosage of any medicine without your doctor's approval.
Disclaimer:Content on this page is for informational purposes only. Do not consume prescription medication without a registered practitioner's direct oversight.